Pfizer\u304cGene Therapy\u306b\u95a2\u3059\u308b\u6280\u8853\u3092\u52df\u96c6\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n
Pfizer is committed to leading in this space by bringing together the foremost expertise in vector design and development with in-house knowledge of disease biology and manufacturing capabilities. Our current collaboration with Spark Therapeutics Inc. on Hemophilia B, with Sangamo Therapeutics Inc. on Hemophilia A and our acquisition of Bamboo Therapeutics, form the basis upon which we intend to continue building our gene therapy programs and capabilities. We see gene therapy as a key pillar of our Rare Disease strategy. In addition we are interested in the application of gene therapy to select central nervous system (CNS) and heart diseases. We are also seeking promoter technologies, as well as industry-leading vector analytics and immune surveillance approaches, and in-vivo gene editing technologies.\u00a0–<\/p>\n
We are interested in partnering to develop and access:<\/p>\n
-Novel Targets in key areas of interest<\/p>\n
\u2013 Parkinson\u2019s Disease<\/p>\n
\u2013 Huntington\u2019s Disease<\/p>\n
\u2013 Spinal Muscular Atrophy<\/p>\n
\u2013 Muscular Dystrophy<\/p>\n
\u2013 Alzheimer\u2019s Disease<\/p>\n
\u2013 Sickle Cell Disease<\/p>\n
-Novel AAV vectors with strong tissue-specific tropism (CNS, liver, and heart) with favorable transduction\/expression<\/p>\n
-Promoter or gene regulation technology to ensure regulated and sustained tissue-specific gene expression<\/p>\n
-Vector analytics to identify viruses with superior bioactivity<\/p>\n
-AAV immunology expertise to test\/challenge existing hypotheses and develop more robust gene therapy products<\/p>\n
\u203b\u4ee5\u4e0a\u306e\u6280\u8853\u30cb\u30fc\u30ba\u60c5\u5831\u306f\u3001\u30cb\u30fc\u30ba\u63d0\u4f9b\u8005\u304c\u516c\u5f0f\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8\u3084\u5c55\u793a\u4f1a\u306a\u3069\u306b\u516c\u958b\u3057\u3066\u3044\u308b\u3082\u306eJTG\u306b\u3066\u53d6\u5f97\u3057\u7de8\u96c6\u3057\u305f\u3082\u306e\u3067\u3059\u3002<\/p>\n","protected":false},"author":18,"featured_media":1333,"template":"","meta":{"_company_name":"Pfizer","_job_location":"","_application":"skimura@keisenassociates.com","_company_tagline":"Gene Therapy\u306b\u95a2\u3059\u308b\u6280\u8853\u3092\u52df\u96c6\u3057\u3066\u3044\u307e\u3059\u3002","_company_video":"","_company_website":"https:\/\/www.pfizer.com\/partners\/highlights","_company_twitter":"","_filled":0,"_featured":0,"_remote_position":0,"_job_salary":"","_job_salary_currency":"","_job_salary_unit":""},"job_listing_region":[],"job-categories":[65,68,69,70],"job-types":[52,53],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-listings\/1485"}],"collection":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-listings"}],"about":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/types\/job_listing"}],"author":[{"embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/users\/18"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/media\/1333"}],"wp:attachment":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/media?parent=1485"}],"wp:term":[{"taxonomy":"job_listing_region","embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job_listing_region?post=1485"},{"taxonomy":"job_listing_category","embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-categories?post=1485"},{"taxonomy":"job_listing_type","embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-types?post=1485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}